Drop the Nycomed, keep the Amersham, said shareholders at the May 9 company meeting. The change will take place “as soon as practicable,” according to
Drop the Nycomed, keep the Amersham, said shareholders at the May 9 company meeting. The change will take place “as soon as practicable,” according to Amersham.
Computed Tomography Study Assesses Model for Predicting Recurrence of Non-Small Cell Lung Cancer
January 31st 2025A predictive model for non-small cell lung cancer (NSCLC) recurrence, based on clinical parameters and CT findings, demonstrated an 85.2 percent AUC and 83.3 percent sensitivity rate, according to external validation testing in a new study.